Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging and multiparametric magnetic resonance imaging (mpMRI) of the prostate have improved diagnostic workup in prostate cancer (PCa), especially in patients with advanced disease [1,2]. This evidence concerns the gene FOLH1 and prostate carcinoma.